Is Hims & Hers Health Stock a Buy?
Telehealth company Hims & Hers Health (NYSE: HIMS) has been great for investors this year by almost any standard; share prices have nearly doubled from a year ago. Yet shareholders aren't feeling the joy. The stock is down nearly 45% since peaking in June, and the negative momentum is weighing on investors. The market is suddenly questioning whether the company can succeed.
One concern being raised is that deep-pocketed Amazon now offers telehealth solutions. Does Hims & Hers stand a chance? Another concern is that the Ozempic shortage will eventually end, and investors are panicking about what that might mean for Hims & Hers.
These burning questions need answers, and that can only come by taking a deeper dive into this stock's financials. Here is what you need to know.
Source Fool.com
